Wnt/β-catenin pathway as a potential target for Parkinson's disease: a cohort study of romosozumab using routinely collected health data in Japan

• 主要な著者: Shoichiro Inokuchi (著者), Koji Shimamoto (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

IntroductionRomosozumab is a monoclonal antibody approved for osteoporosis which targets sclerostin, an endogenous inhibitor of Wnt/β-catenin pathway. Given the essential roles of the Wnt/β-catenin pathway in various tissues, we hypothesized romosozumab treatment may influence other conditions.Metho...